2022
Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
Han R, Yang H, Ling C, Lu L. Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer Cell International 2022, 22: 368. PMID: 36424626, PMCID: PMC9685933, DOI: 10.1186/s12935-022-02786-6.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTNBC cellsBreast cancer treatmentNegative breast cancerCaspase-3 activity analysisExpression levelsSpheroid formation assayFurther RT-PCRTNBC patientsTumor burdenEarly recurrencePoor prognosisAggressive subtypeChemotherapy responseAlternative therapiesPreclinical studiesTNBC progressionMouse modelTherapeutic implicationsPreclinical experimentsSurvival rateTherapeutic useClinic practiceLevel assays
2021
Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
Han R, Yang H, Lu L, Lin L. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis. Scientific Reports 2021, 11: 8626. PMID: 33883691, PMCID: PMC8060393, DOI: 10.1038/s41598-021-88133-7.Peer-Reviewed Original ResearchConceptsLiver cancer developmentLiver cancerCancer developmentLiver cancer cell linesCD133 expression levelsAnti-proliferation effectQuantitative reverse transcription PCRCancer cell linesCancer deathTHLE-3THLE-3 cellsAlternative therapiesReverse transcription-PCREffective therapyFatal causeNC groupTherapeutic implicationsInvasion assaysTherapeutic useClinic practiceELISA kitHigher anti-proliferation effectColony formationTranscription-PCRAnticancer efficacy